Harrow Q4 revenue $66.8M (+84% YoY), net income $6.8M; FY2025 guidance >$280M

HARROW, INC.

Q4 revenue $66.8M (+84% YoY); FY2024 revenue $199.6M (+53% YoY).
GAAP net income Q4 $6.8M vs loss $9.1M; Adjusted EBITDA Q4 $22.5M vs $2.6M.
IHEEZO unit demand +43% QoQ to 49,130 units; VEVYE prescriptions +44% QoQ, approaching 5% DED market share.
TRIESENCE awarded CMS transitional pass-through (April 2025-2028); five-year supply agreement with CMO; next-gen NDA by 2027.
FY2025 revenue guidance 'over $280M' (>40% YoY); cash $47.2M; met leverage ratio, avoided warrant issuance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.